We show here that CD8 T cells from tuberculosis (TB) patients recognize HLA-E-binding M. tuberculosis peptides in a CD3/TCR αβ mediated and CD8-dependent manner, and represent an additional type of effector cells playing a role in immune response to M. tuberculosis during active infection. HLA-E-restricted recognition of M. tuberculosis peptides is detectable by a significant enhanced ex vivo frequency of tetramer-specific circulating CD8 T cells during active TB. These CD8 T cells produce type 2 cytokines upon antigenic in vitro stimulation, help B cells for Ab production, and mediate limited TRAIL-dependent cytolytic and microbicidal activity toward M. tuberculosis infected target cells. Our results, together with the finding that HLA-E/M. tuberculosis peptide specific CD8 T cells are detected in TB patients with or without HIV coinfection, suggest that this is a new human T-cell population that participates in immune response in TB.
Introduction
T-cell-mediated immune responses play a fundamental role in fighting against Mycobacterium tuberculosis [1, 2] . Traditionally, this response is mediated by Th1-type CD4 T cells secreting IFN-γ [2, 3] , but it has become clear that CD8 T cells also contribute to protective immunity against M. tuberculosis [4] by the release of Th1-type cytokines and cytotoxic and microbicidal molecules that promote killing of M. tuberculosis infected macrophages and restrict the growth of intracellular bacilli [2] . In humans, M. tuberculosis reactive CD8 T cells recognize peptides associated to classical HLA-A, HLA-B, and HLA-C class I (class Ia) molecules, glycolipids associated to group 1 CD1 molecules [5, 6] , and mycobacterial Ag associated to MHC class I related molecule (MR1) [7] . However, there is little information on the role that these cells play during infection. In mice, the MHC class Ib molecule H2-M3 binds formylated peptides derived from M. tuberculosis and induces H2-M3-restricted CD8 T cells [8, 9] that are protective against M. tuberculosis infection [10] .
In humans, CD8 T cells restricted by class Ib molecules comprise the very large majority of the overall M. tuberculosis specific CD8 T-cell response [11] and CD8 T cells recognizing M. tuberculosis Ags in the context of the class Ib molecule HLA-E have been isolated from subjects with latent M. tuberculosis infection [12, 13] . However, the functions of this HLA-E-restricted population, as well as its contribution to the host response to M. tuberculosis during infection and disease, remain unknown.
HLA-E is the least polymorphic of all the HLA molecules [14] with only two alleles in the Caucasian population, which differ at one aa position located outside the peptidebinding groove [15] . Physiologically, HLA-E binds nonamer peptides derived from the signal sequence of other HLA class I molecules [16, 17] , and the HLA-E/peptide complex in turn binds to CD94/NKG2A (inhibitory) and CD94/NKG2C (activating) NK receptors [17] [18] [19] . However, HLA-E also binds peptides derived from self-Ags [20, 21] , tumors [22] , and pathogenic microorganisms [13, [23] [24] [25] [26] , including M. tuberculosis [11] [12] [13] , and presents them to CD8 T cells.
The lack of allelic variation in the peptide-binding groove may be advantageous to design peptide-based vaccines against tuberculosis (TB). In fact, while the polymorphism of MHC class Ia molecules is an obstacle for clinical application of these peptidebased vaccination strategies, vaccines based on peptides presented by HLA-E are suitable for the global heterogenic population.
In addition to its limited polymorphism, HLA-E offers another potential advantage in relation to M. tuberculosis infection. As opposed to HLA-A and HLA-B molecules, HLA-E is resistant to HIV-nef-mediated downregulation [27, 28] . This is particularly relevant in view of the high prevalence of HIV/M. tuberculosis coinfection in countries such as South Africa where approximately 70% of TB patients are also HIV infected [29] . Thus, while HIV might affect recognition of M. tuberculosis coinfected macrophages [30] by HLA class Ia molecules, HLA-E-dependent Ag presentation and target-cell recognition are likely to be less or not affected at all by HIV coinfection. Therefore, targeting M. tuberculosis specific HLA-E-restricted responses by vaccination or immunotherapy might be a novel and advantageous approach to combat TB.
In this article we have studied the epitope specificity, functional attributes, and ex vivo frequencies of HLA-E-restricted CD8 T cells specific for M. tuberculosis peptides in patients with active TB. We show here that HLA-E-restricted CD8 T cells recognize M. tuberculosis peptides in a CD3/TCR αβ mediated and CD8-dependent manner. Moreover, we provide evidence that during active TB disease, these cells produce type 2 (Tc2) cytokines, help B cells for Ab production, and have very poor TRAIL-mediated cytolytic activity and microbicidal potential. Finally, using HLA-E/M. tuberculosis peptide tetramers we show that the frequency of such tetramerspecific CD8 T cells declines after successful chemotherapy, indicating that this novel human T-cell population participates in immune response in TB.
Results

Identification of predicted HLA-E-binding M. tuberculosis peptides
A recent study using a combination of several bioinformatic methods has led to the identification of 69 potential HLA-E-binding peptides from the total M. tuberculosis H37Rv genome [13] . Despite differences in their binding affinities to recombinant human HLA-E, 79% peptides were recognized by at least one healthy purified protein derivative (PPD) responder, in a CD8 T-cellproliferation assay [13] . Thus, and as found for other HLA class I molecules as well [31] , actual affinities determined in this biochemical cell-free binding assay do not fully correlate with epitope recognition by CD8 T cells. Therefore 18 peptides (Supporting Information Table 1 ) were chosen to represent groups of six peptides each that display high, intermediate, and low binding affinity to HLA-E molecule in a cell-free assay, and these peptides were screened for their capability to induce HLA-E cell surface expression and to elicit peptide-specific response of CD8 T cells from at least 30% of patients with active TB disease.
To test the capacity of the M. tuberculosis peptides to bind HLA-E, we performed a stabilization assay [17, 18, 32] in which TAPdeficient RMA-S (TAP2 mutant Rauscher Murine Leukemia virusinduced T cell lymphoma) cells transfected with HLA-E (RMA-S/HLA-E) were cultured in the presence or absence of peptide at 37°C overnight and cell-surface expression of HLA-E analyzed by flow cytometry.
In the absence of peptide, there was no evidence of HLA-E expression (Supporting Information Fig. 1A ). The canonical VMAPRTLIL sequence (used as a positive control) identical to that present in the leader sequence of most HLA-C alleles [33] was able to stabilize HLA-E expression. Interestingly, culture with M. tuberculosis peptide 44 resulted in the highest levels of HLA-E expression. Peptide 34 also stabilized HLA-E cell surface expression although not to the extent of peptide 44. Coculture with peptides 62 and 68 resulted in somewhat lower, but significant surface levels of HLA-E expression compared to peptide 44, while peptide 55 stabilized only poorly HLA-E molecules on RMA-S/HLA-E cells. All other tested M. tuberculosis peptides failed to stabilize HLA molecules on transfected RMA-S cells. Together the data demonstrated that 5 of the 18 tested M. tuberculosis peptides (i.e. peptides 34, 44, 55, 62, and 68) were able to stabilize surface expression of HLA-E, albeit to varying degrees.
In parallel with the analysis of HLA-E surface expression, the 18 M. tuberculosis peptides were tested for their capability to induce proliferative responses of CD8 T cells from ten patients with active TB. Peptide-induced CD8 T-cell responses were scored positive when exceeding 10% proliferation in the absence of peptide (see Materials and Methods and [13] ), in at least 30% of the tested TB patients. According to these criteria, a total of 4 of the 18 tested peptides (i.e. peptides 34, 55, 62, and 68) were found to elicit a CD8 T-cell response (Supporting Information Fig. 1B) . When HLA-E surface expression and CD8 T-cell response results were compared, peptides 34, 62, and 68 were found capable of stabilizing HLA-E surface expression and eliciting a CD8 T-cell response; peptide 44 caused the highest HLA-E surface expression but a very low CD8 T-cell response and conversely, peptide 55 induced relatively low HLA-E surface expression but significant CD8 T-cell response.
Therefore, because HLA-E cell surface stabilization did not fully correlate with the CD8 T-cell response, in subsequent experiments we decided to use the five peptides that gave a positive result in either assay.
HLA-E/M. tuberculosis peptide complexes are not recognized by CD94/NKG2 receptors
The C-type lectin receptors CD94/NKG2A and CD94/NKG2C specifically interact with HLA-E, resulting either in inhibition or activation of NK-cell function [17] [18] [19] . Therefore we tested the ability of M. tuberculosis peptides to affect target-cell lysis by NKcell clones expressing either CD94/NKG2A or CD94/NKG2C.
In order to address whether complexes of HLA-E and M. tuberculosis peptides inhibit lysis mediated by CD94/NKG2A + NK cells, the HLA class I negative K562 cells were transfected with HLA-E (K562/HLA-E) and were incubated overnight at 37°C with either M. tuberculosis peptides or the VMAPRTLIL peptide (used as control) and tested as targets in a 51 Cr release assay (Fig. 1A) .
As expected, K562/HLA-E cells were efficiently killed by CD94/NKG2A + NK-cell clones (e.g. 26.3 and 7.1 clones) and incubation of target cells with the VMAPRTLIL reference peptide was able to protect them from killing (Fig. 1A) . Preincubation of NK cells with anti-CD94 mAb reversed inhibition of cytolysis, demonstrating recognition of HLA-E/VMAPRTLIL complexes by the inhibitory CD94/NKG2A receptor (Fig. 1A) . In contrast, all tested M. tuberculosis peptides failed to protect K562/HLA-E cells from killing by CD94/NKG2A + NK-cell clones and cytotoxicity was not (or was only minimally) altered by the presence of anti-CD94 mAb (Fig. 1A) . We then investigated whether HLA-E molecules loaded with M. tuberculosis peptides are recognized by NK-cell clones expressing a functional activatory CD94/NKG2C receptor. To this end, RMA-S/HLA-E cells incubated with either M. tuberculosis peptides or the VMAPRTLFL reference peptide (used as control) were tested as targets in a 51 Cr release assay with the CD94/NKG2C + NKcell clones 41.3 and 21.6 as effectors. VMAPRTLFL-loaded RMA-S/HLA-E cells were killed more efficiently than control target cells (i.e. unpulsed RMA-S/HLA-E) and lysis of VMAPRTLFL-pulsed RMA-S/HLA-E cells was inhibited on mAb-mediated masking of CD94 (Fig. 1B) . In contrast, incubation of RMA-S/HLA-E cells with the M. tuberculosis peptides had no impact on target-cell recognition by CD94/NKG2C + NK-cell clones and the presence of anti-CD94 mAb did not alter target-cell lysis. Taken together, these results indicate that complexes of HLA-E and M. tuberculosis peptides do not engage inhibitory or activatory CD94/NKG2 receptors.
Recognition of HLA-E/M. tuberculosis peptides requires the TCR αβ and is CD8 dependent
To further investigate the Ag-recognition requirements of the HLA-E-binding M. tuberculosis peptide-responding T cells in more detail, we examined responses in three TB patients against five peptides using peptide-specific polyclonal CD8 T-cell lines generated by peptide stimulation of PBMCs. Donors were selected on the grounds that (i) there was peptide-dependent were cultured for 24 h with an equal number of irradiated K562/HLA-E cells pulsed or unpulsed with peptides, and TNF-α production assessed by ELISA. (B) CD8 T cells were stimulates as in (A) but in the presence of the indicated blocking mAbs. After 24 h, the supernatants were collected and TNF-α levels were assessed by ELISA. Data are shown as mean ± SD (n = 3) and are pooled from two independent experiments, each performed in triplicate. *p < 0.001 when compared to control, as calculated by the Mann-Whitney U test.
CD8 T-cell-proliferative response in that specific donor and (ii) sufficient PBMCs were available. Phenotype characteristics of the lines are summarized in Supporting Information Table  2 All the tested CD8 T-cell lines exhibited fine Ag specificity and strict HLA-E dependence, as demonstrated by their capability to produce TNF-α only when stimulated by K562/HLA-E cells loaded with the specific peptide. Figure 2A shows primary data obtained with five representative T-cell lines. In no case TNF-α production was detected by stimulation of CD8 T-cell lines with peptidepulsed K562 cells (data not shown).
To assess the contribution of the TCR or NK receptors and HLA-E interaction to target-cell recognition, we performed mAb blocking experiments, in which peptide-loaded K562/HLA-E cells were used to stimulate TNF-α production by CD8 T-cell lines. As shown in Figure 2B , significant inhibition of TNF-α production was observed in the presence of blocking mAbs to CD3, TCR αβ, CD8, pan-HLA class I, or HLA-E molecules. Blocking mAbs specific for NKG2D, NKG2C, CD94, or HLA-A/B/C molecules had no inhibitory effect on this process, while capable to inhibit killing of target cells by NK or HLA-A*0201-restricted CD8 T-cell clones (Supporting Information Fig. 3 ).
Together, these data unveil the requirement for TCR αβ mediated and CD8-dependent recognition of HLA-E-binding M. tuberculosis peptides.
Functional properties of HLA-E-restricted and M. tuberculosis specific CD8 T cells
To assess the cytokine profile of HLA-E-restricted and M. tuberculosis specific CD8 T cells, we stimulated T-cell lines with specific peptides and tested cytokine production by ELISA in 24-h supernatants. All 15 CD8 T-cell lines produced TNF-α and 2 lines also produced low yet detectable levels of IL-2 ( Fig. 3A) . Additionally, 9 of the 15 tested cell lines produced significantly IL-4 and IL-13, either alone or in combination with, IL-5, IL-10, and/or TGF-β, while we failed to detect production of IFN-γ, IL-17, and IL-22. Cytokine production was strictly peptide specific as no significant cytokine production was detected with T-cell lines stimulated by peptides different than those used to generate the line. Figure  3B shows representative specificity results with two different CD8 T cell lines, E#34-1 and E#68-3.
Even if the generation of HLA-E-restricted CD8 T-cell lines was carried out under neutral culture conditions (i.e. with IL-2 and in the absence of polarizing cytokines), we cannot exclude that their cytokine pattern may be biased by prolonged in vitro stimulation. Therefore, we decided to define the cytokine produced by CD8 T cells directly ex vivo upon stimulation of PBMCs from seven patients with active TB disease with M. tuberculosis peptides. Intracellular cytokine staining confirmed the dominant IL-4 and IL-13 cytokine production by the CD8 + T cells and the lack of IFN-γ secretion. Primary data from seven TB patients (with PBMCs) stimulated with peptide 68 are shown in Supporting Information Figure 4 . Thus, and differently from CD8 T cells recognizing M. tuberculosis peptides in the context of HLA-class Ia molecules [31, [34] [35] [36] [37] , CD8 T cells recognizing M. tuberculosis peptides presented by HLA-E have an unorthodox Tc2-like, multifunctional phenotype. Therefore, we looked into whether these cells support B cells to secrete Ig. To that end, CD8 T-cell lines were cultured in the With regard to their potential ability to develop cytotoxic responses, only 3 of the 15 tested CD8 T-cell lines were equipped with specific lytic activity, E#44-1, E#55-2, and E#68-1 (Fig. 4A) , as shown by their ability to kill K562/HLA-E cells pulsed with the specific peptide (Fig. 4B) . Most notably, the three cytotoxic CD8 T-cell lines were also able to kill K562/HLA-E or human monocytic THP-1 target-cell lines infected with virulent M. tuberculosis (Fig. 4C) , indicating that the HLA-E-restricted peptides they recognize are generated during natural infection. However, HLA-E-restricted CD8 T-cell lines only minimally reduced the viability of intracellular M. tuberculosis (Fig. 4D ) in K562 and THP-1 target-cell lines. As a control, an HLA-A*0201-restricted CD8 Tcell clone specific for M. tuberculosis Ag 16-kDa 120-128 was fully able to reduce the viability of intracellular M. tuberculosis.
To further elucidate the mechanisms responsible for killing of CD8 T cells recognizing M. tuberculosis peptides in the context of HLA-E, we individually inhibited the granule exocytosis-, TRAIL-, TNF-α-, and FasL-mediated (FasL is Fas ligand) pathways. In agreement with flow cytometry data (Supporting Information Table 2 ), treatment of CD8 T cells with concanamycin A (CMA), an inhibitor of vacuolar type H + -ATPase that blocks perforinbased cytotoxic activity, had no effect on killing of peptide-treated K562/HLA-E-cell targets (Supporting Information Fig. 5 ), thus excluding involvement of the perforin pathway. Addition of mAbs against TRAIL-R1 and TRAIL-R2 caused 82-86% inhibition of target-cell killing, indicating that TRAIL played a major role in the killing activity of HLA-E-restricted CD8 T-cell lines. Finally, mAbs to FasL and TNF-α failed to significantly inhibit the cytotoxicity of all three tested HLA-E-restricted CD8 T-cell lines.
Validation of HLA-E-restricted and M. tuberculosis specific CD8 T cells using tetramers
Using HLA-E/peptide tetramers for four HLA-E-binding peptides, direct ex vivo recognition by TB patients CD8 T cells was demonstrated for all four M. tuberculosis epitopes ( Fig. 5A and B) . In all tested individuals, specificity of tetramer staining was confirmed by the absence of staining among PBMCs from ten normal, uninfected donors using the same M. tuberculosis tetramers (Fig. 5A ).
Although there was considerable variability in the proportions of CD8 T cells that bound to single tetramers, the ex vivo frequency of tetramer-specific CD8 T cells was higher in TB patients than in latent tuberculosis infection (LTBI) subjects and this difference attained statistical significance with all epitopes. Significant differences in frequencies of epitope-specific CD8 T cells were observed in TB patients before and after chemotherapy: in all instances mean frequencies of epitope-specific CD8 T cells significantly decreased after therapy and differences attained statistical significance with most of the studied epitopes (i.e. peptides 44, 55, and 62). Finally, and most notably, the highest mean frequency of tetramer-specific CD8 T cells was found in three TB patients who were coinfected by HIV, which declined after antituberculous therapy as well. Figure 5A shows FACS analysis of the CD8 + tetramer + T cells of one individual from any tested group and
Figure 5B shows cumulative data from 24 patients with active TB disease before and after therapy, and 11 LTBI individuals. As five TB patients were typed as HLA-A*0201 + and we had available HLA-A*0201/M. tuberculosis peptide tetramers, we followed up the CD8 T-cell response to HLA-A*0201-and HLA-Erestricted epitopes in the same patients during therapy. As shown in Figure 6 , the frequencies of HLA-E-epitope-restricted CD8 T cells significantly decreased after 6-month therapy, while mean frequencies of HLA-A*0201-restricted, epitope-specific (ESAT-6, Rv1490, Ag85, and 16-kDa Ags) CD8 T cells increased after therapy. Thus, the opposite trend of HLA-E-and HLA-A*0201-restricted responses strongly suggests these two CD8 T-cell populations may play different roles during M. tuberculosis infection and disease.
Discussion
Within recent years, it has become clear that HLA-E can present peptides from several bacteria and viruses to CD8 + T cells in a manner comparable to peptides presented by classical MHC class I molecules [14, 24, [38] [39] [40] [41] [42] . Indeed, HLA-E-restricted CD8 + T-cell recognition of peptides from pathogens may be an important mechanism of immune regulation during infections, as was first demonstrated for M. tuberculosis [12, 13] . HLA-E is enriched in the M. tuberculosis phagosome compared to regular HLA class I molecules [43] , suggesting that HLA-E may have unique functions in presenting phagosomal Ags. Because M. tuberculosis resides in immature phagosome, the probability that some peptides derived from M. tuberculosis could be presented to CD8 T cells during active infection in association with HLA-E molecules is intriguing. Accordingly, careful examination of HLA-E-restricted CD8 + T-cell responses to peptides from M. tuberculosis found such responses to a number of these peptides [13] . Therefore in our study, we were interested in examining whether TB patients had a detectable CD8 + T-cell response to peptides derived from M. tuberculosis, which have been shown capable to bind to HLA-E. Cumulative data on the frequencies of the tetramer-specific CD8 T cells in peripheral blood of 11 LTBI subjects (black columns) and 24 TB patients with active (gray columns) or cured (white columns) TB disease. Data are shown as mean + SD (n = 3) and are representative of three independent experiments. *p < 0.01 and **p < 0.02 when compared to patients with active TB disease, as calculated by the Mann-Whitney U test.
In this article, using a selected pool of M. tuberculosis peptides capable to stabilize the HLA-E molecule on the surface of transfected cells and to induce proliferation of CD8 T cells in PBMCs from at least 30% TB patients, we provide direct evidence that during active TB HLA-E-restricted CD8 T cells can recognize such M. tuberculosis peptides, thus representing an additional type of effector cells playing a role in immune response to active infection with M. tuberculosis.
Usually, HLA-E/peptide complexes may serve as a ligand for CD94/NKG2A or C, which are NK-cell-inhibitory and NK-cellactivating receptors, respectively [17, 18] . CD94/NKG2A appears to bind ligand with higher affinity, which has led to the notion that HLA-E/peptide complexes may protect target cells from NK-cell-mediated killing [44, 45] . Conversely, engagement of CD94/NKG2C promotes NK-cell killing [44, 45] . In theory, presentation of the M. tuberculosis derived peptides by HLA-E molecule may have similar consequences. However, and in contrast to the HLA-E/self-peptide complexes, we did not find recognition of HLA-E/M. tuberculosis peptide complexes by NK-cell clones selectively expressing inhibitory (NKG2A) or activatory (NKG2C) receptors. Thus, we propose that HLA-E/M. tuberculosis peptide complexes may have very low or even impaired affinity for CD94/NKG2A or C receptors. Moreover, using T-cell lines generated from PBMCs of TB patients by long-term peptide stimulation in vitro, we . This was initially suspected by the lack of expression of perforin and granulysin, and confirmed by the finding that only 3 of the 15 tested HLA-E-restricted M. tuberculosis specific CD8 T-cell lines lysed these target cells. Nonetheless, killing of targets occurred in a peptide-specific and HLA-E-dependent fashion, strongly suggesting peptide/HLA-E cognate recognition via the TCR. Moreover, these epitopes are also likely recognized during natural infection, since live M. tuberculosis infected K562/HLA-E and THP-1 cell lines were lysed by HLA-E/peptide-specific effector CD8 T cells. However, despite their capability to kill peptide-pulsed and M. tuberculosis infected target cells, all three HLA-E-restricted CD8 T-cell lines caused only minimal, if any inhibition of M. tuberculosis outgrowth from these infected human cell lines, indicating that they are equipped with cytolytic potential but lack microbicidal activities. The latter finding could indicate that HLA-E-restricted M. tuberculosis peptide specific CD8 T cells during active TB have an impaired ability to inhibit M. tuberculosis outgrowth, since in another study (submitted) we find that T-cell clones from latently infected individuals were able to inhibit M. tuberculosis outgrowth from infected primary human macrophages. Alternatively, experimental differences (e.g. the use of cell lines here versus primary cells in our other study) might account for this seeming difference. In any case, the lack of correlation between target-cell apoptosis and antimicrobial activity by M. tuberculosis specific CD8 T cells is not surprising and was first reported by Modlin and co-workers [5] . In addition to their poor cytolytic capacity, HLA-E/peptidereactive CD8 T-cell lines from TB patients also had an unusual Tc2-type pattern of cytokine production: they secreted TNF-α and two lines also produced low, yet detectable, levels of IL-2. However, and surprisingly, 9 of the 15 tested cell lines secreted IL-4 and IL-13, either alone or in combination with IL-5, IL-10, and/or TGF-β, while very low or no production of IFN-γ, IL-17, and IL-22 was detected. The cytokine production profile of HLA-E-restricted CD8 T-cell lines was confirmed by intracellular staining of freshly isolated CD8 T cells stimulated with M. tuberculosis peptides. Thus, HLA-E/M. tuberculosis peptide specific CD8 T cells more closely resemble Tc2 T cells and accordingly they are capable to provide help to B lymphocytes for Ab production. Moreover, the finding that some CD8 T-cell lines also secrete TGF-β suggests that a fraction of these cells might play regulatory activities, as shown by previous studies in autoimmune disease models [46] and response to microorganisms [47] , including TB [13] .
Overall, data reported here differ from previously described HLA-E-restricted, TB-specific CD8 T cells that produce IFN-γ and are cytolytic [12, 13] . However, we would like to point that in the Heinzel paper [12] only two HLA-E-restricted and TB-specific CD8 T-cell clones were studied, both derived from one healthy LTBI subject, and cytotoxic activity of the clones was not assessed. Similarly, in the Joosten paper [13] only two of four tested HLA-Erestricted CD8 T-cell lines produced IFN-γ and all four lines killed BCG-infected targets but also exerted TGF-β-mediated suppressive activities. None of the studies investigated the microbicidal properties of HLA-E-restricted CD8 T cells. In our studies, CD8 T-cell lines were generated from patients with active TB and a total of 15 CD8 T-cell lines were tested. Moreover, the cytokine producing profile of the T-cell lines was also evident when CD8 T cells were stimulated ex vivo with HLA-E-binding M. tuberculosis peptides.
Using HLA-E/peptide tetramers for four recognized HLA-Ebinding M. tuberculosis derived peptides, direct ex vivo recognition by TB patients' CD8 T cells was demonstrated for all four epitopes and frequencies of peptide/tetramers in TB patients declined 6 months after the antimycobacterial therapy. One may speculate that expansion of HLA-E-restricted and M. tuberculosis specific CD8 T cells during active TB disease might be the consequence of active replication of M. tuberculosis residing in immature phagosomes. Since HLA-E is enriched within the M. tuberculosis phagosome, as compared to HLA class I molecules, the probability that endogenous peptides derived from M. tuberculosis could be presented to CD8 T cells in association with HLA-E molecules is very high during active TB disease but diminishes after successful therapy. In this case, the frequency of HLA-E-restricted/M. tuberculosis peptide specific CD8 T cells may be a TB-specific biomarker of bacterial load during active infection, which is also rapidly regulated during successful chemotherapy.
In conclusion, our studies have identified CD8 T cells from TB patients, which recognize M. tuberculosis derived peptides presented by HLA-E molecules, produce type 2 cytokines upon antigenic in vitro stimulation, mediate B-cell help for Ab production, and have very limited TRAIL-dependent cytolytic activity and microbicidal potential toward M. tuberculosis infected human cell lines expressing HLA-E. These data, together with the finding that the frequency of HLA-E/M. tuberculosis peptide specific CD8 T cells declines after successful chemotherapy in TB patients with or without HIV coinfection, suggest that this is a new human T-cell population involved in TB.
Future studies are then needed to better dissect this HLA-Erestricted response and to precisely determine the relative importance of effector/protective versus immunoregulatory/pathogenic mechanisms within this response during M. tuberculosis infection and disease.
Materials and methods
Human subjects
Peripheral blood was obtained from 24 adults with TB disease (15 men, 9 women, age range 42-61 years) from the Dipartimento di Medicina Clinica e delle Patologie Emergenti, University Hospital, Palermo, 15 LTBI subjects (10 men, 5 women, age range 38-59 years), and 10 tuberculin-negative healthy subjects (7 men and 3 women, age range 40-57 years).
TB-infected patients had clinical and radiological findings consistent with active pulmonary TB [48] . Diagnosis was confirmed by bacteriological isolation of M. tuberculosis in 14 patients. Other patients were classified as having highly probable pulmonary TB on the basis of clinical and radiological features that were highly suggestive of TB and unlikely to be caused by any other disease; the decision was made by the attending physician to initiate anti-TB chemotherapy, which resulted in an appropriate response to therapy. All patients were treated in accordance with Italian guidelines and received therapy for 6 months. Treatment was successful in all participants all of whom completed the full course of anti-TB chemotherapy, as shown by the absence of any clinical or radiographic evidence of recurrent disease and sterile mycobacterial cultures. Peripheral blood was collected before (TB0) and 4 (TB4) and 6 months after completion of chemotherapy (TB6). None of the TB patients had been vaccinated with BCG, or were being treated with steroid or other immunosuppressive or antitubercular drugs at the time of their first sampling. Three patients had evidence of HIV infection. Tuberculin (PPD) skin tests were considered positive when the induration diameter was larger than 10 mm at 72 h since injection of 5 U of PPD (Statens Seruminstitut, Copenhagen, Denmark).
Individuals with LTBI were defined as healthy people with a positive tuberculin (PPD) skin test and no symptoms and signs of active TB [49] . However, because the response to QuantiFERON-TB Gold test was found in 73% (11/15) of PPD-positive LTBI subjects, only those 11 subjects positive to QuantiFERON TB Gold test were considered as being latently infected and were included in the study. All of the LTBI subjects were health-care workers, and thus very likely to be close contacts of TB index cases. Moreover, none of the LTBI subjects included in this study had been vaccinated with BCG.
Ethics statement
The study was approved by the Ethical Committee of the University Hospital, Palermo, where the patients were recruited. The study was performed in accordance to the principles of the Helsinki Declaration and those of the "Good Clinical Practices," and all individuals gave written informed consent to participate.
Peptide-HLA-E binding assays
Murine TAP2-deficient T-cell lymphoma RMA-S-cell line cotransfected with human β2-microglobulin and HLA-E*01033 allele (RMA-S/HLA-E, kindly provided by J. E. Coligan, Laboratory of Immunogenetics, NIAID, Rockville, MD, USA) was used in the experiments. RMA-S/HLA-E cells were resuspended in complete Roswell Park Memorial Institute medium at 1 × 10 6 cells/mL and incubated either alone or in the presence of the synthetic peptides (200 μM). The M. tuberculosis derived peptides used in these experiments are derived from [13] and are listed in Table 1 . The canonical VMAPRTLIL peptide sequence, identical to that present in most HLA-C alleles [33] , was used as a positive control in binding experiments.
After an overnight incubation at 37°C, cells were washed with PBS to remove free peptides. Next, HLA-E surface expression was monitored after staining with the anti-HLA class I mAb A6.136 (IgM, produced in our laboratory) followed by appropriate PE-conjugated goat antimouse Ab.
CD8 T-cell proliferation induced by M. tuberculosis peptides
PBMCs were labelled with CFSE (5 mM, Molecular Probes, Eugene, OR, USA) and 10 5 cells were stimulated with M. tuberculosis derived HLA-E-binding peptides at a concentration of 10 μg/mL in complete RPMI 1640 medium (Euroclone, Devon, UK) supplemented with 10% heat-inactivated pooled human AB + serum, 2 mM L-glutamine, 20 mM HEPES, 100 U/mL penicillin, 100 μg/mL streptomycin, and 5 × 10 −5 M 2-mercaptoethanol (complete medium) in the presence of 5 ng/mL IL-7 (Peprotech, Rocky Hill, NJ, USA), as described in [13] . Positive (PHA, 1μg/mL; Life Technologies, Paisley, UK) and negative (medium only) controls were included in each assay. On day 7 of culture, cells were harvested, replicates (n = 6) pooled and stained using CD3-PerCP, CD8-APC, and CD56-PE (BD Biosciences, San José, CA, USA) before acquisition on a FACSCalibur using CellQuest Pro software (BD Biosciences).
To analyze proliferation, cells were gated on lymphocytes, followed by gating on CD3 + CD8 + CD56 − cells. The percentage of proliferation was calculated using geometric means by subtracting the geometric mean of all cells from the geometric mean of the undivided population. Subsequently, the percentage was calculated by the following: (delta geo mean of sample − delta geo mean of negative control)/delta geo mean of maximal proliferation [13] . 
NK-cell cytolytic activity
NK-cell clones were tested for cytolytic activity in a 4-h 51 Crrelease assay as described [50] in the presence or absence of anti-CD94 mAb Y9 (IgM, 10μg/mL). Target cells used in these experiments were RMA-S/HLA-E (described above) and the human erythroleukemic cell line K562 transfected with HLA-E*0103 (K562/HLA-E, kindly provided by E. H. Weiss, Department of Biology, Anthropology and Human Genetics, Ludwig-MaximiliansUniversität, Munich, Germany) [51] . Target-cell lines were previously incubated overnight at 37°C, either alone or in the presence of the synthetic peptides (200 μM). Peptides were kept throughout the assay to assure higher levels of HLA-E expression. E:T ratios used in experiments are indicated in figures.
Generation of CD8 T-cell lines and functional assays
PBMCs from TB patients were cultured with 10 μg/mL of M. tuberculosis derived peptides at 3 × 10 6 cells/well in complete medium and human recombinant IL-2 (40 U/mL) [52] . Every 3 days, the culture was refreshed by medium plus IL-2 (40 U/mL). After 15 days, cultures were restimulated weekly with an equal number of peptide-pulsed irradiated (120 Gy from a Caesium source) K562/HLA-E cells, in the presence of 40 U/mL IL-2 and 15 ng/mL IL-15. After four to five cycles of restimulation, the enriched population contained >80% CD8 + T cells (also see Table 2 ). Cells were restimulated weekly as described earlier.
CD8 T-cell lines were analyzed in detail by flow cytometry. Fluorochrome-conjugated antibodies used for staining included CD3 (HIT3a or SK-7, BD Biosciences), CD8 (RPA-TB or SK1, BD Biosciences), CD45 (2D1, BD Biosciences), CD56 (B159, BD Biosciences), CD94 (HP-3D9, BD Biosciences), CD16 (3GB, BD Biosciences), TCR αβ (WT31, BD Biosciences), NKG2A (134111, R&D Systems), NKG2C (1381, R&D Systems), Granzyme B (GB11, BD Biosciences), rabbit anti-human granulysin (a kind gift of Dr. A. Krensky, Stanford, CA, USA) in combination with goat-anti-rabbit FITC (BD Biosciences), TRAIL (RIK-2, eBioscience), perforin (dG9, eBiosciences), or isotype-control mAbs.
Samples were acquired on a FACSCanto and analyzed using FACSDiva software (BD Biosciences). Scoring was based on the percentage of cells that expressed the particular marker, and markers expressed by 10% of the cells, or more, were considered positive. The gating strategy is shown in Supporting Information Figure The cytotoxic activity of CD8 T-cell lines was assessed following 6-h incubation with unpulsed or peptide-pulsed K562 or K562/HLA-E target cells at an E:T ratio of 10:1. Evaluation of dead cells was performed by flow cytometry after incubation with annexin-V-FLUOS staining kit (Roche Diagnostics, Milan, Italy) for the detection and quantification of apoptosis and differentiation from necrosis at single cell level, based on Annexin-V-labeling. In some experiments, cytotoxic assay was carried out in the presence mAbs to FasL (CD95L, 2C101, Vinci Biochem, Firenze, Italy), TNF-α (Infliximab, a gift of Prof. G. Triolo, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Palermo, Italy), or TRAIL receptors 1 (DR4) and 2 (DR5), both provided by Dr. H. Walczak (Tumor Immunology Unit, Division of Medicine, Imperial College, London, UK). To inhibit perforin-mediated cytotoxicity CD8 T-cell lines were incubated with CMA (Sigma, St. Louis, MO, 15 nM final concentration) for 30 min at 37°C prior to coculture, without further washing. Pretreatment of CD8 T-cell lines with CMA at the concentration used in this study did not have any cytotoxic effect.
Cytotoxicity of M. tuberculosis cells and assessment of viability of M. tuberculosis
THP-1-, K562-, and K562/HLA-E-cell lines were infected for 24 h at 37°C, 5% CO 2 with single-cell suspensions of M. tuberculosis H37Rv strain at a multiplicity of infection of 10. The infection was carried out in the absence of antibiotics, and post treatment, cells were washed with PBS to eliminate extracellular bacteria. Viability of infected cells was determined by trypan blue exclusion. Infected or uninfected THP-1-cell line and K562/HLA-E cells were extensively washed and added to peptide-specific CD8 T-cell lines at an E:T ratio of 10:1. After 6 h of coculture, cytotoxicity of target cells was assessed by flow cytometry, as previously described, after incubation with annexin-V-FLUOS staining kit (Roche Diagnostics).
M. tuberculosis infected THP-1-, K562-, and K562/HLA-E-cell lines were incubated with peptide-specific CD8 T-cell lines for 20 h at 37°C as described above, washed three times to eliminate bacteria that were not cell associated, lysed with 0.1% saponin, and sonicated for 20 s. Serial tenfold dilutions were made in 7H9 broth and plated on 7H10 agar plates. Plates were sealed in plastic, kept at 37°C, and the number of colonies (CFUs) was counted after 14-21 days [53] .
A human HLA-A*0201-restricted CD8 T-cell clone specific for M. tuberculosis Ag 16-kDa 120-128 [52] was used as a positive control.
Intracellular cytokine staining
PBMCs (10 6 /mL) were stimulated with peptides in the presence of monensin for 6 h at 37°C in 5% CO 2 . The cells were harvested, washed, and stained with anti-CD8 mAb (RPA-TB, BD Biosciences) in incubation buffer (PBS-1% FCS-0.1% Na azide) for 30 min at 4°C. The cells were washed twice in PBS-1% FCS and fixed with PBS-4% paraformaldehyde overnight at 4°C. Fixation was followed by permeabilization with 1% PBS, 0.3% FCS, 0.1% saponin, and Na azide for 15 min at 4°C. Staining of intracellular cytokines was performed by incubation of fixed permeabilized cells with anti-IFN-γ (25723.11, BD Biosciences), anti-IL-2 (MQ1-17H12, BD Biosciences), anti-TNF-α (MAb11, BD Biosciences), anti-IL10 (BT-10, eBioscience), anti-IL-17A (eBio64DEC17, eBioscience), anti-IL-4 (BD Biosciences, 3010.211), anti-IL13 (Biolegend, JES10-5A2) mAbs or isotype-matched control mAbs. Cells were acquired and analyzed by FACS as described above. Analysis was performed on a minimum of 100 000 CD8 events acquired for each sample. Negative controls were obtained with CD8 T-cell lines incubated with medium, in the absence of any stimulant. Cut-off values for a positive response were predetermined to be in excess of 0.01% responsive cells [31, 37] . Results below this value were considered negative and set to zero [31, 37] .
Tetramer staining
Tetramer staining was carried out as described in detail previously [31, 37, 54] . PBMCs (10 6 /mL) were incubated in U-bottom 96-well plates, washed twice in PBS containing 1% FCS (Sigma), and stained for 30 min at 4°C with PE-labeled tetramers (5 μL each) prepared as previously described [31, 37, 54] ; they were washed and subsequently stained with FITC-labeled anti-CD8 mAb (RPA-TB, BD Biosciences) and analyzed by flow cytometry on a FACSCanto. Data were analyzed with the use of FACSDiva (BD Biosciences). Viable lymphocytes were gated by forward and side scatter and the analysis was performed on 100 000 CD8 events acquired for each sample. A cutoff of 0.01% was used as described previously [31, 37] ; values below this were set to zero.
Ab production in vitro
CD8 T-cell help in Ab production was studied according to [55] .
HLA-E-restricted CD8 T-cell lines or CD8 T cells isolated from the PBMCs of healthy donors were cocultured with sorted tonsillar B cells in 96-well plates at 10 5 cells/well each of T and B cells, in RPMI 1640 medium supplemented with 10% heatinactivated FCS, 2 mM L-glutamine, 20 nM HEPES, and 100 U/mL penicillin/streptomycin. Ten days later IgG and IgM levels in the culture supernatants were determined by ELISA.
Statistics
Nonparametric Mann-Whitney U test was used to determine statistical differences in the distribution of the results. Values of p < 0.05 were considered significant. Data were analyzed using statistical software SYSTAT 11 (Systat Software).
